Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews

IDEAYA Biosciences -0.64%

IDEAYA Biosciences




In the last three months, 6 analysts have published ratings on IDEAYA Biosciences (NASDAQ:IDYA), offering a diverse range of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 3 0 0 0
Last 30D 1 0 0 0 0
1M Ago 0 2 0 0 0
2M Ago 2 1 0 0 0
3M Ago 0 0 0 0 0

Analysts have set 12-month price targets for IDEAYA Biosciences, revealing an average target of $52.33, a high estimate of $57.00, and a low estimate of $43.00. This upward trend is evident, with the current average reflecting a 29.53% increase from the previous average price target of $40.40.

price target chart

Decoding Analyst Ratings: A Detailed Look

A comprehensive examination of how financial experts perceive IDEAYA Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Justin Zelin BTIG Announces Buy $55.00 -
Anupam Rama JP Morgan Raises Overweight $57.00 $51.00
Gregory Renza RBC Capital Raises Outperform $53.00 $43.00
Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00
Corinne Jenkins Goldman Sachs Raises Buy $53.00 $36.00
Gregory Renza RBC Capital Raises Outperform $43.00 $36.00

Key Insights:

  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to IDEAYA Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEAYA Biosciences compared to the broader market.
  • Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

For valuable insights into IDEAYA Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on IDEAYA Biosciences analyst ratings.

Delving into IDEAYA Biosciences's Background

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

Unraveling the Financial Story of IDEAYA Biosciences

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Challenges: IDEAYA Biosciences's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -2.49%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: IDEAYA Biosciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -865.76%, the company may face hurdles in effective cost management.

Return on Equity (ROE): IDEAYA Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.01% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): IDEAYA Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.74%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: IDEAYA Biosciences's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Significance of Analyst Ratings Explained

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via